Overview of Dr. Sherman
Dr. Eric Sherman is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 24 years. He is one of 495 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
530 East 74th Street
New York, NY 10021
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 2000
NYU Grossman School of MedicineResidency, Internal Medicine, 1993 - 1996
Columbia University Vagelos College of Physicians and SurgeonsClass of 1993
Certifications & Licensure
NJ State Medical License 2019 - 2025
NY State Medical License 1995 - 2025
PA State Medical License 2000 - 2008- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Start of enrollment: 2008 Aug 01
- Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer Start of enrollment: 2009 Dec 01
- Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer Start of enrollment: 2010 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 173 citationsThe Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.Luc G. T. Morris, Raghu Chandramohan, Lyndsay West, Ahmet Zehir, Debyani Chakravarty
JAMA Oncology. 2017-02-01 - 16 citationsPatients with low lying lymph nodes are at high risk for distant metastasis in oropharyngeal cancerNadeem Riaz, Jeremy Setton, Moses Tam, Eric J. Sherman, Felix Ho
Oral Oncology. 2014-09-01 - 106 citationsStrategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced ...Nancy Y. Lee, Heiko Schöder, Brad Beattie, Ryan M. Lanning, Nadeem Riaz
International Journal of Radiation Oncology, Biology, Physics. 2016-09-01
Journal Articles
- Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid CancersSteven M Larson, Sofia Haque, Duan Li, R Michael Tuttle, Mona M Sabra, Alan L Ho, Eric J Sherman, Ravinder K Grewal, James A Fagin, David G Pfister, Ronald A Ghossein, The Journal of Clinical Endocrinology and Metabolism
Lectures
- Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy (SBRT) to treat metastatic anaplastic thyr...2019 ASCO Annual Meeting - 6/1/2019
- Combination of dabrafenib (DAB) and lapatinib (LAP) for the treatment of BRAF-mutant thyroid cancer.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Other
- Anaplastic thyroid cancerSherman EJ, Tuttle RM
http://www.uptodate.com/contents/anaplastic-thyroid-cancer
UpToDate, Wolters Kluwer Health - 2013-04-10
Press Mentions
Addition of Pazopanib to Concurrent Radiotherapy and Paclitaxel in Anaplastic Thyroid CancerJanuary 27th, 2023- Fore Biotherapeutics Presents Positive Interim Data from Phase 1/2a Trial Evaluating FORE8394 in Patients with Advanced Tumors with Activating BRAF Alterations at ESMO 2022September 12th, 2022
- Precision Medicine Advances: Pivotal Studies Led by MSK Published in the New England Journal of MedicineAugust 26th, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
